Elevated Serum Macrophage Migration Inhibitory Factor (MIF) Concentrations in Chronic Kidney Disease (CKD) Are Associated with Markers of Oxidative Stress and Endothelial Activation

被引:47
作者
Bruchfeld, Annette [1 ]
Carrero, Juan J. [2 ]
Qureshi, Abdul R. [2 ]
Lindholm, Bengt [2 ]
Barany, Peter
Heimburger, Olof
Hu, Maowen [3 ]
Lin, Xinchun [3 ]
Stenvinkel, Peter
Miller, Edmund J. [3 ,4 ]
机构
[1] Karolinska Univ Hosp Huddinge, Div Renal Med, Dept Clin Sci Intervent & Technol, Karolinska Inst,CLINTEC, S-14186 Huddinge, Sweden
[2] Karolinska Inst, CLINTEC, Baxter Novum, Stockholm, Sweden
[3] Feinstein Inst Med Res, Manhasset, NY USA
[4] Albert Einstein Coll Med, Bronx, NY 10467 USA
基金
英国医学研究理事会;
关键词
HUMAN ATHEROSCLEROTIC PLAQUES; CHRONIC-RENAL-FAILURE; C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE; TNF-ALPHA; INTERLEUKIN-6; MALNUTRITION; INFLAMMATION; EXPRESSION; MORTALITY;
D O I
10.2119/molmed.2008.00109
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chronic kidney disease (CKD) carries an increased risk of cardiovascular disease (CVD). Macrophage migration inhibiting factor (MIF) is a proinflammatory cytokine implicated in the pathogenesis of sepsis, autoimmune disease, atherogenesis, and plaque instability, and is a known cardiac depressant. This post-hoc, cross-sectional study examined whether MIF serum concentrations are elevated in CKD patients. Our study included CKD 3-5 patients with moderate to severe renal dysfunction (n = 257) (mean age SD; 55 +/- 12 years) and 53 controls (60 +/- 12 years). Serum MIF concentrations, measured by enzyme-linked immunosorbent assay (ELISA), were studied in relation to glomerular filtration rate (GFR), presence of CVD, outcome and inflammatory and oxidative stress markers. MIF was significantly elevated in CKD patients compared with controls (CKD: median 676 (range 118-8275 pg/mL) controls: 433 (142-4707) pg/mL: P = 0.008). MIF was also associated with 8-hydroxy-2-deoxyguanosine (8-OH-dG) levels (rho = 0.26: P = 0.001), a marker of oxidative stress, and ICAM-1 levels (rho = 0.14, P = 0.02), a marker of endothelial activation. However, the elevated MIF concentrations were neither correlated with glomerular filtration rate (GFR) nor inflammatory markers such as CRP. IL-6, and TNF. When combining MIF and IL-6 as a marker of inflammation, a significant increase in risk for CVD was found, but when analyzing all-cause mortality, this did not differ significantly with regard to mortality from inflamed patients with low MIF levels. The data suggest that increased serum MIF levels found in CKD is not caused primarily by poor renal function, but is associated with markers of oxidative stress and endothelial activation and may play a role in vascular disease associated with CKD. (C) 2009 The Feinstein Institute for Medical Research, www.feinsteininstitute.org Online address: http://www.molmed.org doi: 10.2119/molmed.2008.00109
引用
收藏
页码:70 / 75
页数:6
相关论文
共 26 条
  • [11] Macrophage migration inhibitory factor induces MMP-9 expression: implications for destabilization of human atherosclerotic plaques
    Kong, YZ
    Yu, XY
    Tang, JJ
    Ouyang, XS
    Huang, XR
    Fingerle-Rowson, G
    Bacher, M
    Scher, LA
    Bucala, R
    Lan, HY
    [J]. ATHEROSCLEROSIS, 2005, 178 (01) : 207 - 215
  • [12] Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study
    McQueen, Matthew J.
    Hawken, Steven
    Wang, Xingyu
    Ounpuu, Stephanie
    Sniderman, Allan
    Probstfield, Jeffrey
    Steyn, Krisela
    Sanderson, John E.
    Hasani, Mohammad
    Volkova, Emilia
    Kazmi, Khawar
    Yusuf, Salim
    [J]. LANCET, 2008, 372 (9634) : 224 - 233
  • [13] New therapeutic target in inflammatory disease: macrophage migration inhibitory factor
    Morand, EF
    [J]. INTERNAL MEDICINE JOURNAL, 2005, 35 (07) : 419 - 426
  • [14] Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients
    Panichi, V
    Maggiore, U
    Taccola, D
    Migliori, M
    Rizza, GM
    Consani, C
    Bertini, A
    Sposini, S
    Perez-Garcia, R
    Rindi, P
    Palla, R
    Tetta, C
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (05) : 1154 - 1160
  • [15] Associations between circulating inflammatory markers and residual renal function in CRF patients
    Pecoits, R
    Heimbürger, O
    Bárány, P
    Suliman, M
    Fehrman-Ekholm, I
    Lindholm, B
    Stenvinkel, P
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (06) : 1212 - 1218
  • [16] Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor
    Radstake, TRDJ
    Sweep, FCGJ
    Welsing, P
    Franke, B
    Vermeulen, SHHM
    Geurts-Moespot, A
    Calandra, T
    Donn, R
    van Riel, PLCM
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (10): : 3020 - 3029
  • [17] SANCHEZNINO MD, 2008, J AM SOC NEPHRO 1008
  • [18] The expression of macrophage migration inhibitory factor 1α (MIF 1α) in human atherosclerotic plaques is induced by different proatherogenic stimuli and associated with plaque instability
    Schmeisser, A
    Marquetant, R
    Illmer, T
    Graffy, C
    Garlichs, CD
    Böckler, D
    Menschikowski, D
    Braun-Dullaeus, R
    Daniel, WG
    Strasser, RH
    [J]. ATHEROSCLEROSIS, 2005, 178 (01) : 83 - 94
  • [19] Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice
    Schober, A
    Bernhagen, J
    Thiele, M
    Zeiffer, U
    Knarren, S
    Roller, M
    Bucala, R
    Weber, C
    [J]. CIRCULATION, 2004, 109 (03) : 380 - 385
  • [20] Coronary artery disease in end-stage renal disease: No longer a simple plumbing problem
    Stenvinkel, P
    Pecoits, R
    Lindholm, B
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07): : 1927 - 1939